Guidance amended regarding HIV PEP recommendations
The EMI Guidelines www.emitoolkit.ie have been amended regarding the HIV PEP recommendations. Dolutegravir (Tivicay) was added as an option to consider in HIV post exposure prophylaxis in the 2016 revision of the guidelines.
In light of the new data outlined in Epi-Insight July 2018, it is recommended that dolutegravir (Tivicay) is not prescribed or dispensed to women who meet criteria for HIV PEP if they are in the first trimester of pregnancy, actively trying to conceive or of childbearing age without effective contraception in place.
The changes to the guidelines are on pages 39, 40, 41 and 100 (Appendices 7 and 31).